South East Asia Blood Testing Market Size & Outlook, 2025-2033
South East Asia Blood Testing Market Insights
- Based on Reed Intelligence findings, the South East Asia Blood Testing Market reached USD 1470.43 Million in 2024 and is estimated to attain USD 2781.41 Million by 2033.
- From 2026 to 2033, the South East Asia market is expected to grow at a steady CAGR of 7.32%.
- Within the By Offerings category, Solutions dominated in 2024 in terms of market size contribution.
- Over the forecast period, Solutions is forecasted to deliver the fastest growth, positioning it as the most lucrative By Offerings segment.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- As of 2024, South East Asia held 1.56% of the global Blood Testing Market size.
- By 2033, United States is anticipated to capture the largest share of the global Blood Testing Market.
- In Asia Pacific, China is expected to lead the regional Blood Testing Market size by 2033.
- Singapore will remain the fastest-growing market in Asia Pacific, reaching USD 760.92 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 1470.43 Million |
| Market Size In 2033 | USD 2781.41 Million |
| Largest segment | Solutions |
| Units | Revenue in USD Million |
| CAGR | 7.32% (2025-2033) |
| Segmnetation Covered | |
| By Offerings |
|
| By Test Type |
|
| By Method |
|
| By End-Use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
South East Asia Blood Testing Market By Offerings 2025-2033 (USD Million)
| By Offerings | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solutions | XX.x | XX.x | XX.x | 841.82 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Software | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South East Asia Blood Testing Market By Test Type 2025-2033 (USD Million)
| By Test Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glucose Testing | XX.x | XX.x | XX.x | 471.71 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Lipid Panel Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Prostate Specific Antigen (PSA) Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Blood Urea Nitrogen (BUN) Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Thyroid Stimulating Hormone Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South East Asia Blood Testing Market By Method 2025-2033 (USD Million)
| By Method | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Automated | XX.x | XX.x | XX.x | 946.96 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Manual | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
South East Asia Blood Testing Market By End-Use 2025-2033 (USD Million)
| By End-Use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospitals & Clinics | XX.x | XX.x | XX.x | 591.41 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Diagnostic Centers | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Remote Testing | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Others | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
